Home LiteratureArticle Details
PMID: 14668439 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H

Abstract

Small molecule inhibitors of protein kinases are widely used in signal transduction research and are emerging as a major class of drugs. Although interpretation of biological results obtained with these reagents critically depends on their selectivity, efficient methods for proteome-wide assessment of kinase inhibitor selectivity have not yet been reported. Here, we address this important issue and describe a method for identifying targets of the widely used p38 kinase inhibitor SB 203580. Immobilization of a suitable SB 203580 analogue and thoroughly optimized biochemical conditions for affinity chromatography permitted the dramatic enrichment and identification of several previously unknown protein kinase targets of SB 203580. In vitro kinase assays showed that cyclin G-associated kinase (GAK) and CK1 were almost as potently inhibited as p38alpha whereas RICK [Rip-like interacting caspase-like apoptosis-regulatory protein (CLARP) kinase/Rip2/CARDIAK] was even more sensitive to inhibition by SB 203580. The cellular kinase activity of RICK, a known signal transducer of inflammatory responses, was already inhibited by submicromolar concentrations of SB 203580 in intact cells. Therefore, our results warrant a reevaluation of the vast amount of data obtained with SB 203580 and might have significant implications on the development of p38 inhibitors as antiinflammatory drugs. Based on the procedures described here, efficient affinity purification techniques can be developed for other protein kinase inhibitors, providing crucial information about their cellular modes of action.

MeSH Terms
Amino Acid Sequence Animals COS Cells Chlorocebus aethiops Enzyme Inhibitors/pharmacology HeLa Cells Humans Mass Spectrometry Mitogen-Activated Protein Kinases/antagonists & inhibitors,chemistry,isolation & purification Protein Kinase Inhibitors Proteomics Recombinant Proteins/antagonists & inhibitors,metabolism Transfection p38 Mitogen-Activated Protein Kinases
Chemicals
Enzyme Inhibitors Protein Kinase Inhibitors Recombinant Proteins Mitogen-Activated Protein Kinases p38 Mitogen-Activated Protein Kinases
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Godl Klaus
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich, Germany.
Wissing Josef
Kurtenbach Alexander
Habenberger Peter
Blencke Stephanie
Gutbrod Heidrun
Salassidis Kostadinos
Stein-Gerlach Matthias
Missio Andrea
Cotten Matt
Daub Henrik
References (28)
28 references, click to expand
  1. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis.
    Nat Cell Biol. 1999 Jun;1(2):94-7 PMID: 10559880
  2. Exploiting features of adenovirus replication to support mammalian kinase production.
    Nucleic Acids Res. 2003 Nov 1;31(21):e128 PMID: 14576328
  3. Specificity and mechanism of action of some commonly used protein kinase inhibitors.
    Biochem J. 2000 Oct 1;351(Pt 1):95-105 PMID: 10998351
  4. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses.
    Nature. 2002 Mar 14;416(6877):190-4 PMID: 11894097
  5. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems.
    Nature. 2002 Mar 14;416(6877):194-9 PMID: 11894098
  6. Optimization of guanidination procedures for MALDI mass mapping.
    Anal Chem. 2002 Apr 15;74(8):1884-90 PMID: 11985322
  7. Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor.
    J Biol Chem. 2002 Jul 12;277(28):25493-501 PMID: 11964410
  8. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
    Nat Rev Drug Discov. 2002 Jul;1(7):493-502 PMID: 12120256
  9. Protein kinases--the major drug targets of the twenty-first century?
    Nat Rev Drug Discov. 2002 Apr;1(4):309-15 PMID: 12120282
  10. Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein.
    J Virol. 2002 Aug;76(16):8124-37 PMID: 12134018
  11. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids.
    Anal Biochem. 1984 Apr;138(1):141-3 PMID: 6731838
  12. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.
    Nature. 1994 Dec 22-29;372(6508):739-46 PMID: 7997261
  13. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1.
    FEBS Lett. 1995 May 8;364(2):229-33 PMID: 7750577
  14. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase.
    Bioorg Med Chem. 1997 Jan;5(1):49-64 PMID: 9043657
  15. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket.
    Nat Struct Biol. 1997 Apr;4(4):311-6 PMID: 9095200
  16. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors.
    Mol Cell Biol. 1997 May;17(5):2360-71 PMID: 9111305
  17. Structure, expression, and chromosomal localization of human GAK.
    Genomics. 1997 Sep 1;44(2):179-87 PMID: 9299234
  18. RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis.
    J Biol Chem. 1998 May 15;273(20):12296-300 PMID: 9575181
  19. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution.
    Chem Biol. 1998 Jun;5(6):321-8 PMID: 9653550
  20. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase.
    J Biol Chem. 1998 Oct 30;273(44):28766-72 PMID: 9786874
  21. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.
    Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6 PMID: 9873686
  22. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo.
    Oncogene. 1999 Mar 25;18(12):2047-54 PMID: 10321729
  23. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580.
    FEBS Lett. 1999 May 21;451(2):191-6 PMID: 10371163
  24. The protein kinase complement of the human genome.
    Science. 2002 Dec 6;298(5600):1912-34 PMID: 12471243
  25. The specificities of protein kinase inhibitors: an update.
    Biochem J. 2003 Apr 1;371(Pt 1):199-204 PMID: 12534346
  26. Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase.
    J Biol Chem. 2003 Jun 20;278(25):22237-42 PMID: 12637577
  27. Gefitinib.
    Nat Rev Drug Discov. 2003 Jul;2(7):515-6 PMID: 12841190
  28. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.
    Chem Biol. 2000 Jun;7(6):411-22 PMID: 10873834
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2003-12-23
Epub
2003-00-10
Pages
15434-9
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC307585
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]